Morgan Stanley Sticks to Their Hold Rating for NanoString Tech (NSTG)

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on NanoString Tech (NSTGResearch Report), with a price target of $28.00. The company’s shares opened today at $15.66.

According to TipRanks, Savant is an analyst with an average return of -3.4% and a 40.79% success rate. Savant covers the Healthcare sector, focusing on stocks such as NanoString Tech, Guardant Health, and Maravai Lifesciences Holdings.

NanoString Tech has an analyst consensus of Strong Buy, with a price target consensus of $30.60.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $62.56 and a one-year low of $11.12. Currently, NanoString Tech has an average volume of 877.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.

Read More on NSTG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More